EMA Discusses Pivotal Role Of RWE For Six Drugs
Executive Summary
The European Medicines Agency explains how it used real-word evidence during recent deliberations for six products.
You may also be interested in...
EMA Lays Out Plans For Routine Use Of Real-World Evidence
A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year by various European Medicines Agency scientific committees.
Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU
MolMed decided to the withdraw the drug's conditional marketing authorization after Phase III clinical trial results showed that the drug offered no benefit on disease-free survival.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.